Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies

Missak Haigentz, Mimi Kim, Joan Sorich, Janet Lee, Howard Hochster, Manuel Macapinlac, Deepu Mirchandani, Sanjeev Sewak, Anna Pavlick, Matthew Volm, Anne Hamilton, Franco M. Muggia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Our objective was to evaluate the role of amifostine as a cytoprotector in patients with solid tumors receiving the myelosuppressive regimen of gemcitabine/cisplatin combination. Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2). Amifostine at 740 mg/m2, followed by gemcitabine and cisplatin, were given for 2 consecutive weeks, every 4 weeks. Two GP combinations were studied: G 1000 mg/m2 and P 40 mg/m2 days 1, 8 (high dose), and G 800 mg/m2 and P 30 mg/m2 days 1, 8 (low dose). Forty patients were enrolled. Of the 19 patients treated with high-dose GP, 11 (nine patients GP in C1 and GAP in C2, two patients GAP in C1 and GP in C2) completed 2 cycles of therapy. Of the eight non-evaluable patients, five patients dropped out due to toxicity or refusal after treatment with amifostine in C1. Of the 21 patients treated with low-dose GP, 15 (eight patients GP in C1 and GAP in C2, seven patients GAP in C1 and GP in C2) were likewise evaluable. The incidence of grade 3 or 4 hematologic toxicities was similar for GP and GAP during the first 2 cycles of treatment, and there were no statistically significant differences in mean absolute neutrophil count, hemoglobin level and platelet levels between the cycles in each arm. We conclude that amifostine, at 740 mg/m2, does not lead to less myelosuppression when combined with gemcitabine/cisplatin chemotherapy regimens and may possibly contribute to subjective intolerance.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalAnti-Cancer Drugs
Volume14
Issue number4
DOIs
StatePublished - Apr 2003
Externally publishedYes

Fingerprint

gemcitabine
Amifostine
Cisplatin
Neoplasms
Treatment Refusal

Keywords

  • Amifostine
  • Cisplatin
  • Cytoprotection
  • Gemcitabine

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. / Haigentz, Missak; Kim, Mimi; Sorich, Joan; Lee, Janet; Hochster, Howard; Macapinlac, Manuel; Mirchandani, Deepu; Sewak, Sanjeev; Pavlick, Anna; Volm, Matthew; Hamilton, Anne; Muggia, Franco M.

In: Anti-Cancer Drugs, Vol. 14, No. 4, 04.2003, p. 321-326.

Research output: Contribution to journalArticle

Haigentz, M, Kim, M, Sorich, J, Lee, J, Hochster, H, Macapinlac, M, Mirchandani, D, Sewak, S, Pavlick, A, Volm, M, Hamilton, A & Muggia, FM 2003, 'Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies', Anti-Cancer Drugs, vol. 14, no. 4, pp. 321-326. https://doi.org/10.1097/00001813-200304000-00010
Haigentz, Missak ; Kim, Mimi ; Sorich, Joan ; Lee, Janet ; Hochster, Howard ; Macapinlac, Manuel ; Mirchandani, Deepu ; Sewak, Sanjeev ; Pavlick, Anna ; Volm, Matthew ; Hamilton, Anne ; Muggia, Franco M. / Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. In: Anti-Cancer Drugs. 2003 ; Vol. 14, No. 4. pp. 321-326.
@article{cb014775600c4a8cb0ab483617c93e42,
title = "Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies",
abstract = "Our objective was to evaluate the role of amifostine as a cytoprotector in patients with solid tumors receiving the myelosuppressive regimen of gemcitabine/cisplatin combination. Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2). Amifostine at 740 mg/m2, followed by gemcitabine and cisplatin, were given for 2 consecutive weeks, every 4 weeks. Two GP combinations were studied: G 1000 mg/m2 and P 40 mg/m2 days 1, 8 (high dose), and G 800 mg/m2 and P 30 mg/m2 days 1, 8 (low dose). Forty patients were enrolled. Of the 19 patients treated with high-dose GP, 11 (nine patients GP in C1 and GAP in C2, two patients GAP in C1 and GP in C2) completed 2 cycles of therapy. Of the eight non-evaluable patients, five patients dropped out due to toxicity or refusal after treatment with amifostine in C1. Of the 21 patients treated with low-dose GP, 15 (eight patients GP in C1 and GAP in C2, seven patients GAP in C1 and GP in C2) were likewise evaluable. The incidence of grade 3 or 4 hematologic toxicities was similar for GP and GAP during the first 2 cycles of treatment, and there were no statistically significant differences in mean absolute neutrophil count, hemoglobin level and platelet levels between the cycles in each arm. We conclude that amifostine, at 740 mg/m2, does not lead to less myelosuppression when combined with gemcitabine/cisplatin chemotherapy regimens and may possibly contribute to subjective intolerance.",
keywords = "Amifostine, Cisplatin, Cytoprotection, Gemcitabine",
author = "Missak Haigentz and Mimi Kim and Joan Sorich and Janet Lee and Howard Hochster and Manuel Macapinlac and Deepu Mirchandani and Sanjeev Sewak and Anna Pavlick and Matthew Volm and Anne Hamilton and Muggia, {Franco M.}",
year = "2003",
month = "4",
doi = "10.1097/00001813-200304000-00010",
language = "English (US)",
volume = "14",
pages = "321--326",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies

AU - Haigentz, Missak

AU - Kim, Mimi

AU - Sorich, Joan

AU - Lee, Janet

AU - Hochster, Howard

AU - Macapinlac, Manuel

AU - Mirchandani, Deepu

AU - Sewak, Sanjeev

AU - Pavlick, Anna

AU - Volm, Matthew

AU - Hamilton, Anne

AU - Muggia, Franco M.

PY - 2003/4

Y1 - 2003/4

N2 - Our objective was to evaluate the role of amifostine as a cytoprotector in patients with solid tumors receiving the myelosuppressive regimen of gemcitabine/cisplatin combination. Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2). Amifostine at 740 mg/m2, followed by gemcitabine and cisplatin, were given for 2 consecutive weeks, every 4 weeks. Two GP combinations were studied: G 1000 mg/m2 and P 40 mg/m2 days 1, 8 (high dose), and G 800 mg/m2 and P 30 mg/m2 days 1, 8 (low dose). Forty patients were enrolled. Of the 19 patients treated with high-dose GP, 11 (nine patients GP in C1 and GAP in C2, two patients GAP in C1 and GP in C2) completed 2 cycles of therapy. Of the eight non-evaluable patients, five patients dropped out due to toxicity or refusal after treatment with amifostine in C1. Of the 21 patients treated with low-dose GP, 15 (eight patients GP in C1 and GAP in C2, seven patients GAP in C1 and GP in C2) were likewise evaluable. The incidence of grade 3 or 4 hematologic toxicities was similar for GP and GAP during the first 2 cycles of treatment, and there were no statistically significant differences in mean absolute neutrophil count, hemoglobin level and platelet levels between the cycles in each arm. We conclude that amifostine, at 740 mg/m2, does not lead to less myelosuppression when combined with gemcitabine/cisplatin chemotherapy regimens and may possibly contribute to subjective intolerance.

AB - Our objective was to evaluate the role of amifostine as a cytoprotector in patients with solid tumors receiving the myelosuppressive regimen of gemcitabine/cisplatin combination. Patients with advanced solid tumors were randomized to gemcitabine-amifostine-cisplatin (GAP) or gemcitabine-cisplatin (GP) in Cycle 1 (C1) and then were crossed over to the other treatment in Cycle 2 (C2). Amifostine at 740 mg/m2, followed by gemcitabine and cisplatin, were given for 2 consecutive weeks, every 4 weeks. Two GP combinations were studied: G 1000 mg/m2 and P 40 mg/m2 days 1, 8 (high dose), and G 800 mg/m2 and P 30 mg/m2 days 1, 8 (low dose). Forty patients were enrolled. Of the 19 patients treated with high-dose GP, 11 (nine patients GP in C1 and GAP in C2, two patients GAP in C1 and GP in C2) completed 2 cycles of therapy. Of the eight non-evaluable patients, five patients dropped out due to toxicity or refusal after treatment with amifostine in C1. Of the 21 patients treated with low-dose GP, 15 (eight patients GP in C1 and GAP in C2, seven patients GAP in C1 and GP in C2) were likewise evaluable. The incidence of grade 3 or 4 hematologic toxicities was similar for GP and GAP during the first 2 cycles of treatment, and there were no statistically significant differences in mean absolute neutrophil count, hemoglobin level and platelet levels between the cycles in each arm. We conclude that amifostine, at 740 mg/m2, does not lead to less myelosuppression when combined with gemcitabine/cisplatin chemotherapy regimens and may possibly contribute to subjective intolerance.

KW - Amifostine

KW - Cisplatin

KW - Cytoprotection

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=12444307433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444307433&partnerID=8YFLogxK

U2 - 10.1097/00001813-200304000-00010

DO - 10.1097/00001813-200304000-00010

M3 - Article

VL - 14

SP - 321

EP - 326

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -